Hyperpolarized Xenon Gas MR Imaging in NSCLC Radiotherapy
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
Lung cancer is the second most commonly diagnosed cancer in the United Kingdom, accounting
for 22% of cancer deaths. The main treatments for lung cancer are surgery, radiotherapy or
chemoradiotherapy. Current methods, for assessing lung function in lung cancer patients i.e.
spirometry and gas transfer are inadequate. We aim to develop a new technique capable of
describing regional lung abnormality using hyperpolarized xenon gas MRI.
The study will involve 50 patients diagnosed with lung cancer considered suitable for radical
radiotherapy or chemoradiotherapy. Participants will be offered hyperpolarized Xe129 MR at
baseline, two weeks after commencement of radiotherapy schedules and four followup visits
over one year posttreatment.
Patients will undertake extensive study measures at baseline and followup visits, including
chest CT scans, ventilation/perfusion nuclear medicine scans, gadolinium enhanced MRI scans,
pulmonary function tests, breathlessness scores, radiotherapy induced lung toxicity
assessments and exercise testing. Participation in these full tests takes a day, allowing
patients time to rest between tests and allowing for a period of observation following the
final hyperpolarized xenon scan.
The investigators will correlate baseline hyperpolarized Xe129 MR imaging with spirometry and
breathlessness scores to determine if tolerance for radiotherapy is better predicted by
hyperpolarized Xe129 MR imaging. The investigators will evaluate changes in hyperpolarized
Xe129 MR imaging before and after radiotherapy (RT) to determine if it provides better
monitoring of response compared with spirometry.
The study will take place at the Churchill Hospital, Oxford University Hospitals National
Health Service Trust and will be funded by the National Institute for Health Research Oxford
Biomedical Research Centre. Hyperpolarized Xe129 MR imaging has the potential to inform
individual suitability for radiotherapy schedules better than the investigations used
currently. In addition, hyperpolarized Xe129 MR imaging has the potential for better
monitoring of treatment response and improved detection of radiation induced lung injury,
invaluable to treating patients with radiation induced injury.
Phase:
Phase 2
Details
Lead Sponsor:
Oxford University Hospitals NHS Trust
Collaborator:
National Institute for Health Research, United Kingdom